Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681 | Vol. 03, Issue-05, May-2026 | pp.-32-57

ORIGINALARTICLE https://aktpublication.com/index.php/jprims/index

Theranostic Liposomes: Dual-Function Nanocarriers for Drug Delivery and Disease Monitoring

Chetan S Dharne[1,3], Vinay Sagar Verma[2], Aayush Yadav[2], Bhupendra Kumar Sahu[2], Govind Sharma[2]*

[1] Kamla Nehru College of Pharmacy, Butibori, Nagpur, Maharashtra, India. Pin-441108
[2] Kamla Institute of Pharmaceutical Sciences, SSPU, Junwani, Bhilai, Durg, Chhattisgarh, India. Pin-490020.
[3] FPS, Shri Shankaracharya Professional University, Junwani, Bhilai, Durg, Chhattisgarh, India. Pin-490020.

***Corresponding Email: govindsharma10aug@gmail.com**

Abstract:

Theranostic liposomes represent a paradigm shift in precision nanomedicine by integrating therapeutic drug delivery with diagnostic imaging functionality into a single nanocarrier platform. These dual-function systems address long-standing limitations of conventional therapeutics and diagnostics by enabling simultaneous treatment and real-time monitoring of drug biodistribution, tissue accumulation, and therapeutic response. Structurally composed of phospholipid bilayers, liposomes can encapsulate diverse therapeutic agents—from small-molecule chemotherapeutics to macromolecules like proteins and nucleic acids—while co-loading imaging probes including fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, computed tomography (CT) enhancers, and radionuclides for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Through rational design strategies including size optimization, PEGylation for prolonged circulation, ligand-mediated active targeting, and incorporation of stimuli-responsive lipids, theranostic liposomes achieve enhanced pharmacokinetics, selective tumor or tissue accumulation, and controlled release kinetics. Pharmacokinetically, these systems exploit the enhanced permeability and retention (EPR) effect for passive targeting and receptor-mediated endocytosis for active targeting, while multimodal imaging enables quantitative assessment of drug localization and therapeutic efficacy. Clinical applications span oncology, cardiovascular disease, neurological disorders, and infectious diseases—with theranostic platforms enabling personalized dosing adjustments, early prediction of therapeutic outcomes, and reduction of off-target toxicity. Despite remarkable potential, challenges including formulation stability, batch-to-batch reproducibility, cost-effective scale-up, and complex regulatory requirements demand continued innovation. Future developments emphasize smart, stimuli-responsive systems, artificial intelligence-driven optimization, biodegradable hybrid architectures, and personalized liposomal engineering. Collectively, theranostic liposomes embody the convergence of materials science, molecular pharmacology, and imaging technology—redefining precision medicine by seamlessly integrating diagnosis, therapy, and real-time disease monitoring into adaptive, patient-centric treatment paradigms.

Keywords: Theranostic Liposomes, Drug Delivery, Nanocarriers, Targeted Delivery, Bioimaging, MRI Contrast Agents, Fluorescence Imaging, PET/SPECT Imaging, Multimodal Imaging, Pharmacokinetics, Biodistribution, Stimuli-Responsive Systems, Precision Medicine, Dual-Function Nanocarriers, Nanomedicine

Received: Feb. 13, 2026 **Revised: March 16, 2026** **Accepted: April. 28, 2026** **Published: May 04, 2026**

DOI: https://doi.org/10.64063/3049-1681.vol.3.issue5.3

https://aktpublication.com/index.php/jprims/issue/archive

1. Introduction

Liposomes have emerged as one of the most versatile and widely explored nanocarriers in modern pharmacology, owing to their unique structural features, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic agents. Structurally, liposomes are spherical vesicles composed of phospholipid bilayers surrounding an aqueous core, allowing them to carry diverse therapeutic molecules ranging from small-molecule drugs to nucleic acids and proteins. Since their first discovery in the 1960s, liposomes have been extensively investigated and clinically translated for various applications, including anticancer therapy, infectious disease management, and vaccine delivery. Their intrinsic flexibility enables modifications such as PEGylation for prolonged circulation, surface functionalization for targeted delivery, and encapsulation of imaging agents, making them a cornerstone in nanomedicine development. Importantly, liposomes mitigate many limitations associated with conventional drug delivery, including poor solubility, rapid metabolism, systemic toxicity, and non-specific biodistribution, thereby improving therapeutic efficacy and patient outcomes [1-2].

The concept of theranostics—the simultaneous integration of therapeutic and diagnostic functions into a single platform—represents a paradigm shift in personalized medicine. Theranostic liposomes embody this approach by co-encapsulating therapeutic agents and diagnostic moieties such as fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, or radionuclides within a single nanocarrier. This dual functionality allows real-time monitoring of drug biodistribution, accumulation in target tissues, and therapeutic response, thereby bridging the gap between treatment and diagnosis. The potential of theranostic liposomes extends beyond conventional drug delivery by enabling clinicians to adjust dosing, track disease progression, and predict therapeutic outcomes with unprecedented precision. Such integrated platforms are particularly relevant in oncology, cardiovascular disorders, and neurological diseases, where disease heterogeneity and variable patient responses pose significant challenges for conventional therapies.

Theranostic liposomes offer several advantages over traditional drug delivery systems. First, they provide targeted delivery through both passive mechanisms, such as enhanced permeability and retention (EPR) effect in tumor tissues, and active targeting using ligands or antibodies attached to the liposomal surface. Second, the co-delivery of imaging agents ensures non-invasive, real-time tracking of therapeutic distribution and pharmacokinetics, allowing early identification of off-target effects or suboptimal accumulation. Third, liposomal encapsulation can improve drug stability and bioavailability, protect labile molecules from enzymatic degradation, and facilitate controlled release kinetics through stimuli-responsive designs. Fourth,

the modularity of liposomal platforms allows for simultaneous combination therapy, where multiple drugs or drug–diagnostic combinations can be co-encapsulated to enhance synergistic therapeutic effects while minimizing systemic toxicity. Collectively, these advantages position theranostic liposomes as a next-generation strategy in precision medicine, offering both clinical efficacy and mechanistic insight into drug action [3-4].

Despite their potential, the development and clinical translation of theranostic liposomes require careful consideration of multiple factors, including liposome composition, size, surface charge, drug-to-lipid ratio, and choice of diagnostic moiety. The pharmacokinetics, biodistribution, and clearance mechanisms must be tailored to ensure maximal therapeutic benefit while minimizing adverse effects. Moreover, the regulatory landscape for theranostic agents is complex, as these platforms merge drugs and diagnostics, requiring rigorous evaluation of both therapeutic efficacy and imaging performance. Standardization of manufacturing, reproducibility, and scale-up processes are equally critical to ensure clinical viability. The integration of theranostic liposomes with emerging technologies, including stimuli-responsive systems, hybrid nanocarriers, and artificial intelligence (AI)-driven monitoring, further enhances their potential to revolutionize personalized healthcare.

The objectives of this review are to comprehensively examine the design, development, and clinical potential of theranostic liposomes, highlighting their dual functionality for drug delivery and disease monitoring. Specific emphasis is placed on the physicochemical principles underlying liposome formation, strategies for co-encapsulation of therapeutic and diagnostic agents, and the mechanisms by which these platforms achieve targeted delivery and controlled release. Additionally, the review addresses pharmacokinetic considerations, safety, regulatory perspectives, and current clinical applications, providing a holistic overview of the field. By bridging fundamental nanotechnology with translational pharmacology, this work aims to outline how theranostic liposomes can serve as a paradigm for precision medicine, offering clinicians a powerful tool for personalized, real-time therapeutic intervention [5-6].

In conclusion, theranostic liposomes exemplify the convergence of nanotechnology, pharmacology, and molecular imaging, offering an integrated approach to disease management that overcomes the limitations of conventional therapeutics. Their unique ability to simultaneously deliver drugs and enable diagnostic monitoring provides a platform for real-time therapeutic assessment, improved patient compliance, and precision-guided treatment decisions. As research advances, these dual-function nanocarriers hold immense promise for transforming clinical practice, enabling the next generation of personalized and adaptive therapies across a broad spectrum of diseases.

2. Fundamentals of Liposomes

Liposomes are among the most extensively studied and clinically applied nanocarriers in modern pharmacology due to their unique structural features and versatile functionalization capabilities. Fundamentally, liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. This amphiphilic architecture enables

the encapsulation of both hydrophilic molecules, which reside within the aqueous interior, and hydrophobic compounds, which integrate into the lipid bilayer itself. The lipid composition, typically comprising phosphatidylcholine, phosphatidylethanolamine, cholesterol, and other synthetic or natural phospholipids, directly influences the membrane fluidity, stability, and encapsulation efficiency. Additionally, the outer surface of liposomes can be modified with polymers, targeting ligands, or stealth coatings, which not only enhance systemic circulation but also provide tissue-specific targeting, immune evasion, and controlled drug release. The structural modularity of liposomes allows for the fine-tuning of size, charge, lamellarity, and surface chemistry, which are critical determinants of pharmacokinetics, biodistribution, and therapeutic efficacy [7-8].

Liposomes can be classified into several categories based on composition, surface modification, and functional responsiveness. Conventional liposomes are unmodified vesicles that rely on passive targeting mechanisms such as the enhanced permeability and retention (EPR) effect to accumulate in diseased tissues. While effective for certain applications, these liposomes often exhibit rapid clearance from systemic circulation due to opsonization and uptake by the mononuclear phagocyte system (MPS). To overcome this limitation, stealth or PEGylated liposomes incorporate hydrophilic polymers such as polyethylene glycol (PEG) on their surface, which creates a hydration layer that reduces protein adsorption and prolongs circulation half-life. Cationic liposomes, containing positively charged lipids, are particularly useful for the delivery of nucleic acids, including DNA, RNA, and gene-editing tools, because they form electrostatic complexes with negatively charged biomolecules, facilitating cellular uptake through endocytosis. Stimuli-responsive liposomes represent an advanced class designed to release their payload in response to specific environmental triggers such as pH changes, temperature variations, enzymatic activity, or light exposure. These smart liposomes offer spatial and temporal control over drug release, making them ideal for precision medicine applications where site-specific drug delivery is critical. Table 1 summarizes the major types of liposomes, highlighting their composition, characteristic size ranges, and primary therapeutic and diagnostic applications.

The physicochemical properties of liposomes play a pivotal role in dictating their in vivo behavior and therapeutic performance. Size is a primary factor influencing circulation time, tissue penetration, and cellular internalization; smaller liposomes (typically 50–200 nm) tend to evade rapid clearance and exhibit enhanced accumulation in tumors via the EPR effect. Lamellarity, or the number of lipid bilayers, affects drug loading capacity and release kinetics, with multilamellar vesicles often providing sustained drug release compared to unilamellar counterparts. Surface charge also significantly impacts biodistribution and cellular interactions: neutral or slightly negative liposomes tend to circulate longer, whereas positively charged liposomes show improved uptake by negatively charged cell membranes but may induce cytotoxicity or trigger immune responses. Membrane fluidity, controlled by lipid composition and cholesterol content, governs the stability of the liposome and the permeability of encapsulated drugs. Furthermore, the inclusion of targeting moieties such as

antibodies, peptides, or aptamers allows liposomes to selectively interact with specific cell types or receptors, enhancing therapeutic specificity while reducing off-target effects. Collectively, these physicochemical parameters must be meticulously optimized to achieve the desired balance between stability, delivery efficiency, and diagnostic functionality in theranostic applications [9-10].

A critical advantage of liposomes lies in their inherent biocompatibility and biodegradability, which facilitate safe clinical translation. Phospholipids used in liposome formulation are often similar or identical to naturally occurring components of cell membranes, minimizing immunogenicity and systemic toxicity. Following administration, liposomes can be enzymatically degraded into non-toxic metabolites such as fatty acids and glycerophospholipids, which are readily metabolized by the body. This property not only ensures safety but also reduces long-term accumulation and potential adverse effects, which is particularly important in repeated or chronic therapeutic regimens. Moreover, liposomes are highly versatile and can be engineered to carry a wide range of therapeutics, from small molecules and peptides to nucleic acids and imaging agents, further expanding their clinical relevance across oncology, infectious diseases, cardiovascular therapy, and immunomodulation. Their use in imaging modalities—such as fluorescence, MRI, computed tomography (CT), and positron emission tomography (PET)—allows simultaneous monitoring of drug distribution, tissue targeting, and therapeutic response, thereby bridging the gap between treatment and diagnostics in theranostic platforms.

Surface modifications further enhance the performance of liposomes in both therapeutic and diagnostic applications. Polyethylene glycol (PEG) coatings confer “stealth” properties that minimize immune recognition and opsonization, extending circulation half-life and improving drug accumulation in target tissues. Ligand conjugation enables active targeting to specific cell types, such as tumor cells overexpressing folate receptors or immune cells expressing specific surface markers. Additionally, incorporation of stimuli-responsive elements into the lipid bilayer, such as pH-sensitive or thermosensitive lipids, allows for precise, on-demand release of the therapeutic payload at the disease site. For imaging purposes, liposomes can encapsulate fluorescent dyes, radionuclides, or paramagnetic agents without compromising drug encapsulation, enabling real-time, non-invasive monitoring of therapeutic distribution and efficacy. This dual functionality—therapeutic and diagnostic—defines the unique potential of theranostic liposomes and underscores their transformative role in precision medicine [11-12].

3. Liposome Preparation and Surface Functionalization

The preparation and functionalization of liposomes are fundamental steps in the development of effective and clinically translatable nanocarriers, particularly for theranostic applications that require precise control over drug delivery and diagnostic functionality. Several preparation techniques have been developed to generate liposomes with defined size, lamellarity, and encapsulation efficiency, each offering distinct advantages and limitations depending on the intended application. One of the most widely employed methods is thin-film hydration, which

involves dissolving phospholipids and cholesterol in an organic solvent, followed by solvent evaporation to form a thin lipid film. Hydration of this film with an aqueous buffer results in the spontaneous formation of multilamellar vesicles, which can then be downsized and homogenized through sonication or extrusion to produce unilamellar vesicles with controlled size distributions. This method is particularly versatile, allowing the incorporation of both hydrophilic and hydrophobic molecules, with hydrophobic compounds integrating into the lipid bilayer and hydrophilic compounds entrapped within the aqueous core.

Another prevalent technique is reverse-phase evaporation, which enhances encapsulation efficiency, particularly for hydrophilic drugs. In this method, lipids are dissolved in a mixture of organic solvents and emulsified with an aqueous solution containing the drug of interest. Subsequent solvent removal under reduced pressure leads to vesicle formation with high entrapment efficiency. This approach is beneficial for macromolecular therapeutics, including proteins, peptides, and nucleic acids, as it minimizes degradation and preserves biological activity. Microfluidic-based synthesis represents a more recent advancement, enabling precise control over liposome size, uniformity, and lamellarity through the manipulation of lipid and aqueous flows within microchannels. This method is highly reproducible, scalable, and compatible with high-throughput production, making it suitable for translational and clinical applications. Additionally, extrusion techniques—in which liposomal suspensions are passed through polycarbonate membranes with defined pore sizes—allow fine-tuning of vesicle size and polydispersity, critical factors influencing biodistribution, cellular uptake, and therapeutic efficacy [13-14].

Effective liposome-based theranostics necessitate encapsulation strategies tailored to the physicochemical properties of the therapeutic and diagnostic payloads. Hydrophilic drugs, dyes, or imaging agents are typically entrapped within the aqueous core, while hydrophobic compounds preferentially partition into the lipid bilayer. The choice of lipid composition, cholesterol content, and hydration buffer can significantly influence encapsulation efficiency, stability, and release kinetics. Co-encapsulation of multiple payloads, such as a chemotherapeutic agent with a fluorescent or radionuclide probe, enables simultaneous therapy and imaging, facilitating real-time monitoring of drug distribution and therapeutic response. Advanced strategies, such as pH-sensitive or enzyme-responsive liposomes, allow controlled release at specific pathological sites, enhancing therapeutic index while minimizing off-target toxicity.

Surface functionalization of liposomes is a crucial strategy to improve circulation time, targeting specificity, and overall in vivo performance. The most widely used modification is PEGylation, in which hydrophilic polyethylene glycol chains are grafted onto the liposome surface to create a steric barrier that reduces protein adsorption, opsonization, and recognition by the mononuclear phagocyte system. PEGylated liposomes, also known as stealth liposomes, exhibit prolonged systemic circulation, enhanced accumulation in target tissues, and improved therapeutic outcomes, particularly in oncology applications. Beyond PEGylation, ligand conjugation enables active targeting of liposomes to specific cell types or receptors. Targeting moieties include small

molecules, peptides, antibodies, aptamers, and carbohydrates that recognize overexpressed receptors on tumor cells, inflamed tissues, or immune cells. This active targeting enhances selective uptake, improves intracellular delivery of payloads, and reduces systemic side effects. For theranostic purposes, ligands can be designed to both guide liposomes to disease sites and facilitate imaging, enabling a seamless integration of therapy and diagnosis.

The influence of surface chemistry extends beyond targeting to affect pharmacokinetics, biodistribution, and immunogenicity. Surface charge plays a critical role in cellular interaction: neutral or slightly negative liposomes generally circulate longer, whereas positively charged liposomes exhibit enhanced cellular uptake but may induce cytotoxicity or inflammatory responses. Hydrophobicity, steric hindrance, and ligand density also modulate interactions with serum proteins and cell membranes, thereby influencing in vivo fate. Optimizing these parameters is essential to achieve the desired balance between stability, targeting efficiency, and biocompatibility [15-16].

Achieving reproducibility and long-term stability of liposomal formulations remains a central challenge in their clinical translation. Factors such as lipid composition, encapsulation method, hydration conditions, and storage temperature can affect vesicle integrity, payload retention, and release kinetics. Strategies to enhance stability include the incorporation of cholesterol to reduce membrane fluidity, lyophilization with cryoprotectants, and careful control of pH and ionic strength during formulation. Additionally, scalable production techniques, such as microfluidics and controlled extrusion, are essential to ensure batch-to-batch consistency, a critical requirement for regulatory approval and therapeutic reliability.

In conclusion, the preparation and surface functionalization of liposomes constitute the cornerstone of successful theranostic nanocarrier design. The selection of an appropriate preparation technique—whether thin-film hydration, reverse-phase evaporation, microfluidics, or extrusion—determines vesicle size, lamellarity, and encapsulation efficiency. Encapsulation strategies tailored to the physicochemical properties of payloads, combined with advanced surface modifications such as PEGylation and ligand conjugation, optimize circulation time, targeting specificity, and intracellular delivery. Careful consideration of surface chemistry, charge, and steric properties ensures enhanced pharmacokinetics, biodistribution, and biocompatibility. Finally, strategies to improve stability, reproducibility, and scalability enable the translation of liposomal theranostics from bench to bedside, offering an integrated platform for precision drug delivery and real-time disease monitoring. Table 2 provides a comprehensive overview of the preparation methods, surface functionalization strategies, and key optimization parameters for liposomes, highlighting their clinical potential and versatility in modern nanomedicine [17-18].

4. Mechanisms of Theranostic Action

Theranostic liposomes, as dual-function nanocarriers, embody a sophisticated convergence of drug delivery and diagnostic imaging, enabling simultaneous therapy and disease monitoring in a single platform. The mechanistic foundation of their action lies in two complementary

processes: therapeutic delivery to target tissues and diagnostic signal generation for real-time monitoring of drug biodistribution and treatment response. The therapeutic component of theranostic liposomes relies primarily on both passive and active targeting mechanisms. Passive targeting exploits the enhanced permeability and retention (EPR) effect, a hallmark feature of many pathological tissues, particularly solid tumors. Tumor vasculature is often irregular, fenestrated, and poorly organized, which allows nanosized carriers, typically in the 50–200 nm range, to extravasate from the circulation into the interstitial space preferentially, while normal tissues with intact endothelium largely restrict nanoparticle entry. This phenomenon enhances local drug accumulation without necessitating specific molecular recognition, reducing systemic toxicity and maximizing therapeutic efficacy. Passive targeting, however, is influenced by multiple factors, including liposome size, surface charge, circulation half-life, and vascular permeability of the target tissue. Optimizing these parameters is essential to exploit the EPR effect effectively, ensuring adequate tissue penetration while minimizing clearance by the mononuclear phagocyte system.

Beyond passive targeting, theranostic liposomes employ active targeting strategies to further enhance specificity and cellular uptake. This involves surface functionalization with ligands such as antibodies, peptides, aptamers, or small molecules that selectively bind to overexpressed receptors on target cells. For example, folate-conjugated liposomes preferentially bind to folate receptors on cancer cells, while transferrin-modified liposomes can target cells with upregulated transferrin receptors. Ligand-mediated targeting promotes receptor-mediated endocytosis, facilitating efficient intracellular delivery of encapsulated drugs. Additionally, active targeting can be combined with stimuli-responsive mechanisms—such as pH-sensitive, enzyme-responsive, or redox-sensitive lipids—to trigger drug release specifically in the pathological microenvironment. These approaches collectively enhance therapeutic precision, minimize off-target effects, and enable intracellular delivery to subcellular compartments, which is particularly important for chemotherapeutics, gene therapy, and nucleic acid-based drugs.

The diagnostic dimension of theranostic liposomes leverages their capacity to carry imaging agents in addition to therapeutic payloads. These imaging agents include fluorescent dyes, contrast agents for magnetic resonance imaging (MRI), computed tomography (CT) enhancers, and radionuclides for positron emission tomography (PET). By co-encapsulating imaging probes, theranostic liposomes provide real-time visualization of drug distribution, accumulation, and release kinetics, bridging the gap between therapy and monitoring. Fluorescent dyes, such as near-infrared (NIR) fluorophores, allow deep tissue imaging with high sensitivity and minimal background autofluorescence. MRI contrast agents, typically gadolinium-based chelates or superparamagnetic iron oxide nanoparticles, enable high-resolution anatomical imaging, while CT and PET agents provide quantitative assessment of biodistribution and pharmacokinetics. The combination of these imaging modalities within a single liposomal platform allows multi-modal imaging, facilitating precise diagnosis, therapy guidance, and post-treatment evaluation [19-20].

The dual-function design of theranostic liposomes involves the co-loading of both therapeutic and diagnostic agents without compromising either function. Achieving this requires careful optimization of lipid composition, encapsulation method, and payload compatibility. Hydrophilic drugs and imaging agents are generally entrapped within the aqueous core, whereas hydrophobic molecules integrate into the lipid bilayer. Advanced strategies include sequential loading, layer-by-layer assembly, and the use of hybrid lipid–polymer matrices to maintain stability and prevent premature leakage of either component. Controlled release is often engineered through the use of stimuli-sensitive lipids, which respond to pH, temperature, enzymes, or light at the target site, ensuring that both therapeutic and diagnostic agents are released in a coordinated manner. This integrated approach allows clinicians to monitor drug delivery in real time, assess therapeutic efficacy, and make timely adjustments to treatment regimens, paving the way for precision medicine.

The advantages of theranostic liposomes over separate therapeutic and diagnostic systems are manifold. Firstly, the combined platform reduces the need for multiple administrations, lowering patient burden and improving compliance. Secondly, co-delivery ensures that the imaging signal directly correlates with drug distribution, providing a more accurate assessment of therapeutic outcomes than using separate diagnostic agents. Thirdly, theranostic liposomes facilitate personalized treatment by allowing dose adjustments based on real-time monitoring of drug accumulation and response. Fourthly, the integrated system can help identify non-responders early, minimize adverse effects, and optimize therapeutic regimens. Finally, the nanoscale size and surface tunability of liposomes allow for the incorporation of multifunctional elements, such as targeting ligands, imaging probes, and stimuli-responsive components, which collectively enhance precision, efficacy, and safety.

Mechanistically, the success of theranostic liposomes is also influenced by their physicochemical properties, including size, surface charge, lipid composition, lamellarity, and rigidity. Smaller liposomes (<100 nm) generally penetrate tumors more effectively, whereas larger vesicles may exhibit prolonged circulation but limited tissue penetration. Surface charge influences interactions with plasma proteins, cellular membranes, and the immune system, impacting biodistribution and clearance. PEGylation and other surface modifications prolong circulation and reduce opsonization, while targeted ligands enhance receptor-mediated uptake. The lipid composition determines membrane fluidity, encapsulation efficiency, and release kinetics, which are critical for synchronizing therapeutic and diagnostic functions. Stimuli-responsive lipids further enhance specificity by releasing payloads in response to environmental cues, thereby minimizing off-target effects and maximizing therapeutic index [21-22].

In conclusion, the mechanistic basis of theranostic liposomes involves a delicate interplay of passive and active targeting for therapeutic delivery and multi-modal imaging for diagnostic monitoring. The co-loading of drugs and imaging agents enables simultaneous treatment and visualization, overcoming the limitations of separate therapeutic and diagnostic systems. Careful optimization of liposome size, surface chemistry, lipid composition, and stimuli-responsive features ensures enhanced biodistribution, controlled release, and target-specific accumulation.

By providing real-time feedback on drug localization, efficacy, and safety, theranostic liposomes represent a pivotal advancement in precision medicine, bridging the gap between therapy and monitoring, and enabling personalized, safe, and efficient clinical interventions [23].Figure 1



Figure 1: Mechanistic illustration of theranostic liposome action in vivo.

5. Pharmacokinetics, Biodistribution, and Clearance

The pharmacokinetic and biodistribution profiles of theranostic liposomes are critical determinants of their therapeutic efficacy and diagnostic accuracy. Unlike conventional liposomal formulations that are designed primarily for drug delivery, theranostic liposomes integrate imaging functionality, which requires simultaneous optimization of both therapeutic and diagnostic pharmacokinetics. This integration mandates careful consideration of parameters such as liposome size, surface charge, lipid composition, and surface functionalization—all of which govern their absorption, distribution, metabolism, and excretion (ADME) behavior within biological systems.

Liposome size plays a pivotal role in determining in vivo distribution, circulation time, and tissue penetration. Typically, liposomes ranging from 50 to 200 nm in diameter exhibit optimal pharmacokinetic behavior due to their ability to evade rapid renal clearance while still exploiting the enhanced permeability and retention (EPR) effect in tumors and inflamed tissues. Smaller liposomes (<100 nm) tend to penetrate deeper into tumor interstitium but may also be subject to filtration by the glomerulus if they fall below the renal threshold (~10 nm). Conversely, larger liposomes (>200 nm) are more likely to be recognized and cleared by the mononuclear phagocyte system (MPS), particularly macrophages in the liver and spleen, leading to reduced

systemic circulation and diminished tumor accumulation. Thus, size optimization is a delicate balance between prolonged systemic exposure and sufficient tissue infiltration.

The surface charge of theranostic liposomes profoundly affects their interaction with biological membranes, plasma proteins, and immune cells. Neutral or slightly negative liposomes exhibit extended circulation times because they avoid nonspecific electrostatic interactions with serum proteins and cell membranes. In contrast, positively charged (cationic) liposomes can enhance cellular uptake due to electrostatic attraction to negatively charged cell surfaces but at the cost of rapid clearance and potential cytotoxicity. Moreover, cationic liposomes are more prone to opsonization—the adsorption of plasma proteins that mark them for recognition by macrophages—thereby accelerating removal from circulation. To overcome these challenges, researchers have engineered zwitterionic or PEGylated surfaces to minimize protein adsorption and prolong systemic half-life, achieving a more controlled pharmacokinetic profile suitable for theranostic applications [24-25].

The lipid composition and bilayer rigidity also influence the pharmacokinetic fate of theranostic liposomes. Saturated phospholipids and cholesterol-rich formulations yield rigid bilayers with reduced permeability, improving stability and preventing premature leakage of encapsulated agents. Unsaturated lipids, on the other hand, enhance membrane fluidity, which can facilitate controlled release in response to physiological or pathological stimuli. The inclusion of polyethylene glycol (PEG) conjugates, a process termed PEGylation, creates a hydrophilic "stealth" corona that hinders opsonization and MPS recognition, dramatically increasing circulation time. However, excessive PEGylation may also hinder cell uptake and endosomal escape, creating a "PEG dilemma" that must be optimized depending on the therapeutic objective.

Following intravenous administration, in vivo biodistribution of theranostic liposomes depends heavily on vascular permeability, regional blood flow, and the presence of target receptors. Passive targeting via the EPR effect drives accumulation in tumors, sites of inflammation, and other tissues with leaky vasculature. Active targeting further refines biodistribution by utilizing ligands that recognize cell-specific markers, enabling receptor-mediated endocytosis and intracellular delivery. For instance, liposomes conjugated with antibodies against HER2 preferentially accumulate in HER2-positive breast tumors, while those with folate ligands target ovarian and lung cancers. Additionally, the incorporated imaging agents allow real-time tracking of biodistribution using MRI, PET, or fluorescence imaging, enabling non-invasive quantification of liposome localization and retention [26-27].

Organ-specific accumulation often follows predictable patterns governed by reticuloendothelial system (RES) dynamics. The liver, spleen, and lungs are primary clearance sites, as macrophages in the Kupffer cells and splenic sinusoids efficiently recognize and engulf foreign particulates. In particular, hepatic accumulation is a double-edged sword—it facilitates the treatment of liver-targeted diseases but reduces systemic bioavailability for other tissues. Renal accumulation typically occurs for small or degraded lipid fragments, whereas intact liposomes are too large to pass through the glomerular filtration barrier. The brain, protected by the blood–

brain barrier (BBB), represents one of the most challenging targets. To achieve central nervous system delivery, liposomes must incorporate surface modifications such as transferrin, lactoferrin, or apolipoprotein-mimetic peptides to facilitate receptor-mediated transcytosis across endothelial cells.

Clearance mechanisms of theranostic liposomes involve three primary pathways: uptake by the RES, renal excretion of degraded components, and hepatobiliary elimination. The RES remains the dominant clearance route for most liposomal systems, with macrophages engulfing and degrading liposomes into phospholipid and cholesterol metabolites. Lipid components are further processed by lysosomal enzymes and excreted as bile salts or fatty acids. Hydrophilic degradation products and small imaging agents may undergo renal excretion, depending on their molecular weight and polarity. For hydrophobic agents, hepatobiliary elimination predominates, with metabolites excreted via bile into the gastrointestinal tract. The inclusion of imaging moieties in theranostic liposomes also affects clearance dynamics, as heavy metal–based MRI contrast agents or radiolabeled compounds may exhibit distinct excretion kinetics that must be carefully balanced against therapeutic release profiles [28-29].

To prolong circulation and enhance bioavailability, several strategies have been developed to modulate the pharmacokinetics and clearance of theranostic liposomes. PEGylation, as previously noted, remains the most common approach, extending plasma half-life by creating a steric barrier against opsonization. However, recent studies have shown that repeated administration can induce the production of anti-PEG antibodies, leading to accelerated blood clearance (ABC) upon subsequent doses. Alternative stealth coatings—such as polysarcosine, poly(zwitterions), or hyaluronic acid—are being explored to circumvent this immune response. Another strategy involves charge shielding, where cationic liposomes are temporarily neutralized by pH-sensitive or enzyme-cleavable coatings that detach in the target microenvironment, restoring cellular uptake potential only where needed.

Furthermore, stimuli-responsive liposomes provide a smart means of tuning pharmacokinetics dynamically. For instance, thermosensitive liposomes release their payload in response to local hyperthermia, while pH-sensitive liposomes release drugs preferentially in acidic tumor environments or endosomes. Such designs not only enhance therapeutic efficacy but also improve diagnostic accuracy by ensuring that imaging signals correspond precisely to drug release events. Combining these with magnetic or ultrasound-triggered release mechanisms allows controlled activation under external stimuli, ensuring maximum spatiotemporal control of both therapy and imaging.

In comparison to traditional liposomal formulations, theranostic liposomes exhibit more complex pharmacokinetics due to the dual loading of therapeutic and diagnostic agents. Co-encapsulation can alter lipid bilayer dynamics, affecting stability and release profiles. For example, hydrophobic imaging agents embedded within the bilayer may increase rigidity and slow drug release, while hydrophilic contrast agents in the aqueous core may compete for encapsulation space with hydrophilic drugs. The formulation process, therefore, demands

meticulous optimization to balance both functionalities without compromising pharmacokinetic performance [30-31].

Table 1. Comparative Pharmacokinetics of Conventional vs. Theranostic Liposomes

Parameter	Conventional Liposomes	Theranostic Liposomes	reference
Size Range	50–200 nm	70–250 nm (depending on co-loading)	32
Surface Modification	PEGylated or neutral	PEGylated, ligand-targeted, or stimuli-responsive	33
Circulation Half-life	4–24 hours	6–48 hours (variable by imaging payload)	34
Clearance Mechanism	Primarily RES uptake	RES + renal/hepatobiliary depending on imaging agent	35
Targeting	Passive (EPR effect)	Passive + active targeting with diagnostic tracking	36
Stability	High with optimized lipid composition	Slightly reduced due to co-encapsulation interactions	37
Imaging Capability	None	MRI, CT, PET, or fluorescence enabled	38
Therapeutic Precision	Indirect	Real-time monitored and adjustable	39

6. Therapeutic Applications

Theranostic liposomes have revolutionized the landscape of targeted therapy by integrating therapeutic and diagnostic functionalities within a single nanosystem. Their ability to encapsulate diverse drugs while simultaneously carrying imaging agents enables precise disease diagnosis, real-time therapy tracking, and adaptive treatment decisions. The versatility of liposomal nanocarriers makes them applicable across multiple disease domains, notably oncology, cardiovascular, neurological, and infectious diseases[40].

Oncology remains the most extensively explored application area for theranostic liposomes. Liposomal formulations have been designed to deliver chemotherapeutics directly to tumor sites while providing real-time visualization of tumor accumulation and drug release. The enhanced permeability and retention (EPR) effect, coupled with active targeting through ligands such as folate, transferrin, or monoclonal antibodies, enhances tumor selectivity while minimizing systemic toxicity. For instance, *doxorubicin-loaded theranostic liposomes* co-encapsulated with fluorescent or MRI contrast agents allow simultaneous tumor imaging and chemotherapy monitoring. Such systems enable clinicians to visualize drug biodistribution and assess therapeutic efficacy non-invasively, optimizing dosage regimens. Clinically, formulations like *ThermoDox*®—a temperature-sensitive doxorubicin liposome—have shown promising results in

hepatocellular carcinoma, where heat-triggered release synergizes with localized hyperthermia and MRI tracking to achieve precise spatiotemporal drug delivery.

In cardiovascular diseases, theranostic liposomes have emerged as powerful tools for targeted drug delivery to atherosclerotic plaques and ischemic tissues. They can encapsulate cardioprotective agents such as nitric oxide donors, antioxidants, or anti-inflammatory drugs while carrying contrast agents for imaging vascular lesions. For example, liposomes loaded with gadolinium-based MRI contrast agents have been used to visualize vulnerable plaques and monitor therapeutic responses in real-time. PEGylated liposomes coated with peptides targeting vascular cell adhesion molecule-1 (VCAM-1) or integrins have shown efficient localization to inflamed endothelium. These systems allow clinicians to identify early-stage atherosclerotic changes, deliver therapeutics precisely to lesion sites, and monitor post-treatment recovery—all within one integrated platform [41-42].

The application of theranostic liposomes in neurological disorders represents one of the most innovative frontiers in nanomedicine. The blood–brain barrier (BBB) poses a major obstacle for drug delivery to the central nervous system (CNS). To overcome this, researchers have engineered BBB-penetrating liposomes modified with targeting ligands such as transferrin, apolipoprotein E (ApoE), or cell-penetrating peptides. These functionalized liposomes enable co-delivery of neurotherapeutics (like dopamine agonists, neuroprotective peptides, or siRNA) alongside imaging agents (fluorophores, gadolinium, or radiolabels). Such dual-function systems permit the visualization of brain uptake and therapeutic response in disorders like Alzheimer's, Parkinson's, and glioblastoma. For example, *gadolinium-labeled liposomes encapsulating curcumin* have demonstrated effective MRI tracking and anti-amyloid efficacy in Alzheimer's models, showing the promise of liposomal theranostics in neurodegenerative therapy.

In infectious diseases, theranostic liposomes offer both targeted antimicrobial delivery and infection-site imaging, aiding in early diagnosis and precision therapy. Liposomes encapsulating antibiotics or antifungal agents can be tagged with fluorescent or radioactive tracers to monitor infection dynamics and drug biodistribution. For example, *rifampicin-loaded theranostic liposomes* have shown potent anti-tubercular activity alongside PET imaging for real-time tracking of infection clearance in pulmonary tissues. Similarly, liposomal formulations targeting macrophages have been used for imaging and treating intracellular pathogens such as *Leishmania* and *Mycobacterium tuberculosis*. The ability to visualize therapeutic localization provides an invaluable advantage for assessing treatment efficacy and adjusting dosing in real time [43-44].

Case studies across various preclinical and clinical settings have demonstrated the translational promise of theranostic liposomes. In oncology, *Doxil*® (PEGylated liposomal doxorubicin) has served as a foundational platform for further development of MRI- and fluorescence-integrated variants, enabling visualization-guided chemotherapy. In cardiovascular imaging, *Gd-DTPA-liposomes* have been employed for atherosclerosis detection and plaque characterization. Meanwhile, *radio-labeled liposomal formulations* in PET/SPECT imaging have shown excellent pharmacokinetic predictability and diagnostic accuracy in clinical trials. These examples

collectively highlight how theranostic liposomes are advancing from concept to clinic, bridging the gap between diagnosis and therapy for truly personalized medicine.

7. Imaging Modalities and Diagnostic Potential

The diagnostic dimension of theranostic liposomes is achieved through the incorporation of imaging agents that enable real-time visualization of drug distribution, accumulation, and therapeutic response. By combining therapeutic payloads with diagnostic imaging moieties, these nanocarriers provide a powerful means to track pharmacokinetics, monitor disease progression, and assess treatment efficacy non-invasively. Multiple imaging modalities—including fluorescence, near-infrared (NIR), magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET)/single-photon emission computed tomography (SPECT)—are commonly integrated with liposomal systems to create comprehensive theranostic platforms [45-46].

Fluorescence and near-infrared (NIR) imaging represent widely used approaches due to their simplicity, high sensitivity, and compatibility with a broad range of lipophilic dyes and fluorophores. Fluorescent dyes such as rhodamine, fluorescein, or indocyanine green (ICG) are often incorporated into the lipid bilayer or aqueous core of liposomes to enable optical tracking at cellular and tissue levels. NIR fluorophores, in particular, offer deep tissue penetration and minimal background interference, making them ideal for in vivo imaging. These liposomes are extensively applied in preclinical studies to visualize tumor accumulation, evaluate biodistribution, and guide surgical resection of tumors with real-time fluorescence feedback. For example, *ICG-loaded liposomes* have been successfully utilized for intraoperative imaging of hepatocellular carcinoma and sentinel lymph node mapping.

MRI- and CT-based liposomal systems provide superior spatial resolution and anatomical detail, making them indispensable for non-invasive disease monitoring. Liposomes incorporating gadolinium (Gd^{3+})-based contrast agents or superparamagnetic iron oxide nanoparticles (SPIONs) enhance MRI signal contrast, allowing precise mapping of nanocarrier distribution. These MRI-active liposomes have been developed for tumor imaging, plaque detection, and tracking inflammatory responses. Similarly, liposomes loaded with iodine-based or gold nanoparticle contrast agents enhance X-ray attenuation, improving CT visualization of vascular lesions or tumor vasculature. Such formulations have demonstrated strong diagnostic performance while maintaining biocompatibility and drug stability.

PET and SPECT imaging have further elevated the diagnostic potential of theranostic liposomes by enabling highly sensitive, quantitative, and whole-body imaging. Radioisotopes such as ^64Cu, ^99mTc, and ^111In can be conjugated to lipids or chelating agents embedded in liposomal membranes. These radio-labeled liposomes facilitate real-time tracking of pharmacokinetics and biodistribution in both preclinical and clinical settings. PET-enabled liposomes, in particular, have been used to evaluate tumor uptake, therapeutic retention, and clearance dynamics, offering valuable insights for dosage optimization. Moreover, radiolabeled

theranostic liposomes can guide image-assisted surgery or radiotherapy by pinpointing pathological regions with high precision [47-48].

A growing trend in the field is the development of multiplexed imaging strategies, where liposomes incorporate multiple imaging agents for multimodal visualization. Combining optical, MRI, and nuclear imaging modalities provides complementary data—optical imaging for surface-level resolution, MRI for anatomical context, and PET for quantitative biodistribution. For instance, *dual-modality liposomes* containing SPIONs and NIR dyes enable simultaneous MRI tracking and fluorescence-guided surgery, ensuring accurate tumor resection while minimizing collateral damage. Tri-modal systems integrating PET, MRI, and optical imaging are now being explored to offer real-time, multi-scale insights into both therapeutic delivery and disease progression.

Collectively, theranostic liposomes embody a paradigm shift in diagnostic science by merging therapy and imaging into a unified, synergistic platform. Their ability to visualize biodistribution, predict treatment outcomes, and provide spatiotemporal control represents a leap toward precision medicine. As imaging technologies evolve and nanocarrier engineering advances, future theranostic liposomes are expected to feature higher signal sensitivity, multiplexing capacity, and real-time feedback mechanisms—paving the way for adaptive and patient-specific therapy monitoring [49].

8. Safety, Toxicity, and Regulatory Considerations

The clinical translation of theranostic liposomes relies heavily on their safety, tolerability, and regulatory compliance. Despite the promising preclinical results, assessing their biocompatibility, cytotoxicity, and long-term safety remains a cornerstone for their acceptance in pharmaceutical and clinical applications. Liposomes, owing to their phospholipid-based composition, are generally biocompatible and biodegradable; however, the inclusion of imaging agents, targeting ligands, or metallic nanoparticles may alter their toxicity profile and biological interactions.

Biocompatibility and cytotoxicity assessment are fundamental steps in preclinical evaluation. Drug-loaded liposomes are typically evaluated using *in vitro* cytotoxicity assays such as MTT, LDH release, and hemolysis tests to assess their effect on cellular viability and membrane integrity. *In vivo* studies, involving repeated dosing and histopathological examination of major organs, are used to confirm biocompatibility and systemic safety. Imaging-loaded theranostic liposomes, especially those incorporating gadolinium, iron oxide, or radioactive tracers, demand additional scrutiny for potential metal ion release, oxidative stress, or genotoxicity. PEGylated liposomes generally show reduced opsonization and prolonged circulation, but prolonged exposure may elicit anti-PEG antibodies, potentially leading to accelerated blood clearance (ABC) upon subsequent administrations [50-51].

Long-term safety and immunogenicity are critical considerations for theranostic systems designed for repeated or chronic use. The immune system can recognize modified liposomal

surfaces—particularly those functionalized with antibodies, peptides, or exogenous ligands—triggering complement activation-related pseudoallergy (CARPA). Additionally, liposomes that escape rapid clearance may accumulate in the reticuloendothelial system (RES), particularly in the liver and spleen, raising concerns about potential organ toxicity over time. Monitoring such accumulation and assessing clearance kinetics through imaging techniques are thus essential for optimizing liposomal formulations. Furthermore, the presence of metallic or radiolabeled imaging agents increases the need for precise dosing and biodegradability evaluation to prevent systemic or localized toxicity.

From a regulatory perspective, theranostic liposomes occupy a unique position, as they combine pharmacological (drug) and diagnostic (device or imaging agent) components—qualifying them as combination products under both FDA and EMA frameworks. Regulatory bodies demand comprehensive characterization of these systems, encompassing physicochemical properties, encapsulation efficiency, release kinetics, biodistribution, and long-term biocompatibility. According to FDA guidelines, developers must establish safety and efficacy profiles for both the therapeutic and diagnostic components individually and in combination, demonstrating that the dual-functionality does not compromise performance. Similarly, the European Medicines Agency (EMA) emphasizes the importance of demonstrating reproducibility, nanocarrier stability, and consistency between manufacturing batches. Regulatory authorities also mandate adherence to Good Manufacturing Practices (GMP), validated analytical methods, and stringent quality control for nanocarrier-based therapeutics [52-53].

To facilitate clinical translation and standardization, several strategies are being pursued. These include simplifying liposome compositions to minimize variability, using FDA-approved excipients (e.g., phosphatidylcholine, cholesterol, PEG), and optimizing scalable preparation techniques such as microfluidics. Moreover, establishing standardized testing protocols for toxicity, pharmacokinetics, and imaging performance across laboratories can help reduce regulatory uncertainty. Collaborative efforts among academia, industry, and regulatory agencies are driving the formulation of new nanomedicine-specific guidance documents, addressing the complexity of multifunctional systems. As the field matures, adaptive regulatory frameworks—such as those promoting real-time safety monitoring and phase-wise approval—are expected to accelerate the clinical deployment of theranostic liposomes[54-55].

In summary, while theranostic liposomes hold immense clinical potential, their path to regulatory approval requires meticulous validation of safety, reproducibility, and quality. A balanced approach integrating toxicological assessment, standardized manufacturing, and regulatory harmonization will be key to bringing these dual-function nanocarriers from laboratory benches to bedside applications [56-57].

9. Challenges and Limitations

Despite their versatility and clinical promise, theranostic liposomes face several technological, biological, and economic challenges that hinder widespread clinical translation. These limitations arise from their complex design, stability requirements, and manufacturing

constraints—each of which must be addressed for successful commercialization and patient adoption[58].

A major challenge lies in stability and storage. Liposomes are inherently sensitive to physical and chemical degradation, including phospholipid oxidation, hydrolysis, and aggregation. The incorporation of imaging agents and therapeutic payloads further complicates formulation stability, as their differing physicochemical properties can lead to premature leakage, phase separation, or drug degradation during storage. Maintaining colloidal stability under physiological conditions (pH, ionic strength, and temperature) is also difficult, especially for stimuli-responsive or cationic liposomes. Lyophilization and cryoprotectants are often used to enhance shelf-life, but these techniques can alter vesicle morphology or drug encapsulation efficiency [59-60].

Another critical limitation is reproducibility and large-scale manufacturing. Laboratory-scale preparation methods—such as thin-film hydration or extrusion—often fail to produce consistent particle sizes and encapsulation efficiencies when scaled up. Achieving batch-to-batch reproducibility while maintaining physicochemical uniformity is vital for regulatory compliance. Advanced manufacturing approaches like microfluidic synthesis and high-pressure homogenization offer improved control but remain expensive and require specialized infrastructure. Furthermore, co-loading both therapeutic and diagnostic agents introduces formulation complexity, as each component may require different encapsulation environments (aqueous core vs. lipid bilayer), release kinetics, and stability profiles[61-62].

Functional integration—the simultaneous incorporation of drugs and imaging agents—presents another formidable challenge. Co-loading can result in competitive encapsulation or interference between agents, potentially reducing drug efficacy or imaging signal strength. Balancing the therapeutic payload with optimal imaging contrast often demands iterative optimization of lipid composition, particle size, and surface functionalization. Moreover, imaging agents like gadolinium or SPIONs can alter the liposome's pharmacokinetics or surface charge, leading to unanticipated changes in biodistribution and clearance [63-64].

Patient compliance and cost-effectiveness also play a decisive role in determining clinical feasibility. The high production cost of theranostic liposomes—driven by expensive raw materials, purification steps, and quality control requirements—can limit market adoption, particularly in resource-constrained healthcare systems. Additionally, the complexity of these systems demands specialized imaging infrastructure (e.g., MRI, PET, or NIR equipment), further adding to healthcare costs. From the patient perspective, acceptance may depend on treatment convenience, dosing frequency, and safety profile compared to conventional formulations[65].

Lastly, regulatory and translational barriers remain significant. Since theranostic liposomes straddle the intersection of drugs and devices, their approval process is inherently complex. The lack of universally accepted standards for evaluating multifunctional nanomedicines adds uncertainty for developers. Furthermore, most theranostic liposomes are still in preclinical or early clinical stages, and comprehensive long-term safety data are limited. Bridging the gap

between experimental efficacy and real-world therapeutic benefit requires rigorous clinical trials, cost-benefit analyses, and standardized imaging-based endpoints[66-67].

In conclusion, while the dual-functionality of theranostic liposomes presents an extraordinary leap toward precision medicine, their real-world application depends on overcoming challenges of stability, scalability, reproducibility, and affordability. Continued innovation in formulation engineering, regulatory harmonization, and clinical validation will be crucial to unlocking their full potential as next-generation nanocarriers for integrated therapy and diagnostics [68-69].

10. Future Perspectives

Theranostic liposomes represent a cutting-edge evolution in nanomedicine—bridging therapy and diagnostics into a single, adaptive platform. As research in materials science, molecular biology, and imaging technology progresses, the next generation of liposomal systems is moving toward intelligent, multifunctional architectures capable of autonomous response, real-time monitoring, and precision delivery.

A major future direction lies in stimuli-responsive, smart theranostic liposomes. These nanocarriers can alter their physicochemical behavior in response to endogenous triggers such as pH, redox gradients, enzymes, or external stimuli like temperature, magnetic fields, and light. For instance, tumor microenvironments often display acidic conditions and high glutathione levels—factors that can be exploited to design liposomes that release therapeutic agents specifically at the target site while simultaneously activating contrast agents for imaging. This dual responsiveness not only enhances therapeutic precision but also minimizes systemic toxicity and off-target effects [70-71].

Another transformative area is the integration of artificial intelligence (AI) and advanced imaging analytics. AI-driven algorithms can process massive datasets from real-time imaging, pharmacokinetic modeling, and patient genomics to optimize liposome design and therapeutic regimens. Predictive modeling could identify ideal formulations for individual patients, fine-tune release kinetics, and even anticipate adverse responses. In a clinical setting, this synergy between AI and theranostic liposomes could lead to fully personalized treatment plans—where the dosage, delivery route, and imaging schedule are dynamically adjusted in real time based on patient response.

Multi-functional liposomes are also on the horizon—systems that merge therapeutic, diagnostic, and immunomodulatory capabilities. These advanced platforms could deliver chemotherapeutic agents, visualize tumor response, and simultaneously modulate immune pathways to prevent relapse or metastasis. For example, liposomes co-encapsulating immune checkpoint inhibitors and MRI contrast agents could allow oncologists to visualize tumor regression while tracking immune activation. In the context of infectious or inflammatory diseases, liposomes may serve as both treatment vehicles and biosensors, providing feedback on infection progression or immune status [72-73].

The field is also gravitating toward personalized and real-time theranostics, where liposomal formulations are tailored based on patient-specific genetic, metabolic, or pathological profiles. Combining data from liquid biopsies, imaging biomarkers, and omics platforms could enable custom-designed liposomes with precise drug-to-imaging ratios and targeting ligands suited to a patient's molecular signature. This personalized approach promises to transform treatment paradigms in cancer, neurological disorders, and cardiovascular diseases—making therapy more efficient, safer, and adaptive.

On the translational front, efforts are being made to standardize liposome production through microfluidic manufacturing, which ensures high reproducibility, scalability, and batch-to-batch consistency. Emerging biomanufacturing platforms are integrating automated quality control and imaging-based validation systems, further facilitating regulatory compliance. Additionally, biodegradable and bioresorbable lipid materials are being explored to enhance long-term safety and minimize organ accumulation—critical considerations for chronic or repeated-dose therapies.

Future theranostic liposomes are expected to be modular and hybridized, combining lipids with polymers, peptides, or inorganic nanostructures. Such hybrid systems can incorporate multiple imaging agents (e.g., fluorophores, gadolinium, radionuclides) and therapeutic cargos (e.g., siRNA, small molecules, or CRISPR components) within a single construct. These hybrid platforms will enable multiplexed imaging and combinatorial therapies, pushing the boundaries of precision nanomedicine.

In summary, the future of theranostic liposomes is deeply intertwined with advances in smart materials, computational modeling, and personalized medicine. The ultimate vision is an intelligent, responsive, and patient-specific liposomal system capable of diagnosing, treating, and adapting—ushering in a new era of proactive, data-driven healthcare. As clinical translation accelerates and interdisciplinary innovation continues, these "living nanocarriers" will redefine the landscape of targeted therapy and disease monitoring [74 -75].

11. Conclusion

Theranostic liposomes embody the convergence of two powerful domains—therapy and diagnostics—within a single nanoscale architecture. Through the integration of drugs and imaging agents, these dual-function nanocarriers enable real-time visualization of drug delivery, biodistribution, and therapeutic response, paving the way for more informed and adaptive treatment strategies.

Their structural flexibility, biocompatibility, and tunability make liposomes ideal candidates for precision medicine applications across oncology, neurology, cardiology, and infectious diseases. By enabling both targeted drug release and concurrent imaging, theranostic liposomes significantly enhance treatment efficacy while minimizing systemic toxicity and guesswork in clinical decision-making.

Looking ahead, the development of smart, AI-integrated, and patient-tailored liposomal systems will further blur the lines between diagnosis and therapy. These innovations promise not only to improve treatment outcomes but also to transform the clinical workflow—where continuous monitoring, predictive feedback, and adaptive dosing become standard practice.

Ultimately, theranostic liposomes represent more than just a technological advance—they signify a paradigm shift toward personalized, data-driven, and real-time medicine. As regulatory frameworks mature and translational research expands, these next-generation liposomes stand poised to redefine how we diagnose, treat, and monitor disease in the era of precision healthcare.

References

1. Li, Y., & Fang, B. (2023). Neural stem cell-derived extracellular vesicles: The light of central nervous system diseases. *Biomedicine & Pharmacotherapy, 165*, 115092.
2. Conklin, B., Conley, B. M., Hou, Y., Chen, M., & Lee, K.-B. (2023). Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. *Advanced Drug Delivery Reviews, 192*, 114636.
3. Yadav, V. K., Choudhary, N., Gacem, A., Verma, R. K., Abul Hasan, M., Tarique Imam, M., Almalki, Z. S., Yadav, K. K., Park, H.-K., Ghosh, T., et al. (2023). Deeper insight into ferroptosis: Association with Alzheimer's, Parkinson's disease, and brain tumors and their possible treatment by nanomaterials-induced ferroptosis. *Redox Report, 28*, 2269331.
4. Tashima, T. (2024). Mesenchymal stem cell (MSC)-based drug delivery into the brain across the blood–brain barrier. *Pharmaceutics, 16*, 289.
5. Sánchez-Dengra, B., González-Álvarez, I., Bermejo, M., & González-Álvarez, M. (2023). Access to the CNS: Strategies to overcome the BBB. *International Journal of Pharmaceutics, 636*, 122759.
6. Song, G., Plumlee, P., Ahn, J. Y., Wong, S. T., & Zhao, H. (2023). Translational strategies and systems biology insights for blood–brain barrier opening and delivery in brain tumors and Alzheimer's disease. *Biomedicine & Pharmacotherapy, 167*, 115450.
7. Palaniyappan, R., Arthanari, S., Subramanian, M., Periyasamy, P., Pethappachetty, P., Ganesan, R., Prakash, M., & Govindaraj, A. (2024). Nanotechnology-driven approaches in overcoming drug delivery challenges for neurodegenerative diseases. *Indian Journal of Pharmaceutical Education and Research, 58*(s), s1185–s1200.
8. Hoque, M., Samanta, A., Alam, S. S. M., Zughaibi, T. A., Kamal, M. A., & Tabrez, S. (2023). Nanomedicine-based immunotherapy for Alzheimer's disease. *Neuroscience & Biobehavioral Reviews, 144*, 104973.
9. Duan, M., Cao, R., Yang, Y., Chen, X., Liu, L., Ren, B., Wang, L., & Goh, B.-C. (2024). Blood–brain barrier conquest in glioblastoma nanomedicine: Strategies, clinical advances, and emerging challenges. *Cancers, 16*, 3300.
10. Wu, D., Zhao, J., Xu, T., Xiang, H., Zhao, B., Gao, L., & Chen, Y. (2024). Glioma nanomedicine: Design, fabrication and theranostic application. *Coordination Chemistry Reviews, 505*, 215696.

11. Hersh, A. M., Alomari, S., & Tyler, B. M. (2022). Crossing the blood–brain barrier: Advances in nanoparticle technology for drug delivery in neuro-oncology. *International Journal of Molecular Sciences, 23*, 4153.
12. Ale, Y., & Nainwal, N. (2023). Progress and challenges in the diagnosis and treatment of brain cancer using nanotechnology. *Molecular Pharmaceutics, 20*, 4893–4921.
13. Mishra, A., Kumar, R., Mishra, J., Dutta, K., Ahlawat, P., Kumar, A., Dhanasekaran, S., Gupta, A. K., Sinha, S., Bishi, D. K., et al. (2023). Strategies facilitating the permeation of nanoparticles through blood–brain barrier: An insight towards the development of brain-targeted drug delivery system. *Journal of Drug Delivery Science and Technology, 86*, 104694.
14. Beygi, M., Oroojalian, F., Azizi-Arani, S., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2024). Multifunctional nanotheranostics for overcoming the blood–brain barrier. *Advanced Functional Materials, 34*, 2310881.
15. Tan, Q., Zhao, S., Xu, T., Wang, Q., Zhang, M., Yan, L., Chen, X., & Lan, M. (2023). Inorganic nano-drug delivery systems for crossing the blood–brain barrier: Advances and challenges. *Coordination Chemistry Reviews, 494*, 215344.
16. Nabipour, H., & Rohani, S. (2024). Metal–organic frameworks for overcoming the blood–brain barrier in the treatment of brain diseases: A review. *Nanomaterials, 14*, 1379.
17. Ekhator, C., Qureshi, M. Q., Zuberi, A. W., Hussain, M., Sangroula, N., Yerra, S., Devi, M., Naseem, M. A., Bellegarde, S. B., & Pendyala, P. R. (2023). Advances and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances. *Cureus, 15*, e44302.
18. Daraban, B. S., Popa, A. S., & Stan, M. S. (2024). Latest perspectives on Alzheimer's disease treatment: The role of blood–brain barrier and antioxidant-based drug delivery systems. *Molecules, 29*, 4056.
19. Vargas, R., Lizano-Barrantes, C., Romero, M., Valencia-Clua, K., Narváez-Narváez, D. A., Suñé-Negre, J. M., Pérez-Lozano, P., García-Montoya, E., Martinez-Martinez, N., & Hernández-Munain, C. (2024). Systematic review of surface modification strategies on lipid nanoparticles to overcome the blood–brain-barrier. *International Journal of Pharmaceutics, 665*, 124686.
20. Saeedi, M., Morteza-Semnani, K., Siahposht-Khachaki, A., Akbari, J., Valizadeh, M., Sanaee, A., Jafarkhani, B., Eghbali, M., Zanjani, H. H. H., Hashemi, S. M. H., et al. (2023). Passive targeted drug delivery of venlafaxine HCl to the brain by modified chitosan nanoparticles. *Journal of Pharmaceutical Innovation, 18*, 1441–1453.
21. Shi, S., Ren, H., Xie, Y., Yu, M., Chen, Y., & Yang, L. (2023). Engineering advanced nanomedicines against central nervous system diseases. *Materials Today, 69*, 355–392.
22. Pradhan, N., & Jana, N. R. (2024). Nanomodulators that target Alzheimer's disease: A review. *ACS Applied Nano Materials, 7*, 3515–3545.
23. Georgeous, J., AlSawaftah, N., Abuwatfa, W. H., & Husseini, G. A. (2024). Review of gold nanoparticles: Synthesis, properties, shapes, cellular uptake, targeting, release mechanisms and applications in drug delivery and therapy. *Pharmaceutics, 16*, 1332.

24. McLoughlin, C. D., Nevins, S., Stein, J. B., Khakbiz, M., & Lee, K.-B. (2024). Overcoming the blood–brain barrier: Multifunctional nanomaterial-based strategies for targeted drug delivery in neurological disorders. *Small Science, 4*, 2400232.
25. Damiri, F., Fatimi, A., Paiva Santos, A. C., Varma, R. S., & Berrada, M. (2023). Smart stimuli-responsive polysaccharide nanohydrogels for drug delivery: A review. *Journal of Materials Chemistry B, 11*, 10538–10565.
26. Dhiman, A., Rana, D., Benival, D., & Garkhal, K. (2024). Comprehensive insights into glioblastoma multiforme: Drug delivery challenges and multimodal treatment strategies. *Therapeutic Delivery*, 1–29.
27. Maher, R., Moreno-Borrallo, A., Jindal, D., Mai, B. T., Ruiz-Hernandez, E., & Harkin, A. (2023). Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. *Pharmaceutics, 15*, 746.
28. Wang, R., Zhang, X., Feng, K., Zeng, W., Wu, J., Sun, D., Lu, Z., Feng, H., & Di, L. (2023). Engineered lipoproteins for precise brain disease theranostics. *Asian Journal of Pharmaceutical Sciences, 18*, 100857.
29. Susa, F., Arpicco, S., Pirri, C. F., & Limongi, T. (2024). Overview on physiopathology of the blood–brain barrier and lipid-based nanocarriers for CNS delivery. *Pharmaceutics, 16*, 849.
30. Goswami, S., Isaev, N. K., Salmina, A. B., Rana, S. V. S., Illarioshkin, S. N., & Verma, Y. (2024). Selective therapeutic targeting of functionalized nanomaterials to neurovascular units. *Brain Disorders, 15*, 100162.
31. Dubey, A. K., & Mostafavi, E. (2023). Biomaterials-mediated CRISPR/Cas9 delivery: Recent challenges and opportunities in gene therapy. *Frontiers in Chemistry, 11*, 1259435.
32. Saikia, B., & Dhanushkodi, A. (2024). Engineered exosome therapeutics for neurodegenerative diseases. *Life Sciences, 356*, 123019.
33. Zhang, X., Li, Y., & Hu, Y. (2020). Green synthesis of silver nanoparticles and their preventive effect in Alzheimer's rat model. *Colloids and Surfaces A: Physicochemical and Engineering Aspects, 605*, 125288.
34. Madadi, A. K., & Sohn, M.-J. (2024). Advances in intrathecal nanoparticle delivery: Targeting the blood–cerebrospinal fluid barrier. *Pharmaceuticals, 17*, 1070.
35. Patel, H., Patel, J., & Patel, A. (2024). Enhancement of neuroprotective action in ischemic stroke using T3-loaded nanoparticles. *Medical and Pharmaceutical Journal, 3*, 1–12.
36. Lin, X., Li, N., & Tang, H. (2022). Nanomaterials for diagnosis and treatments in ischemic stroke. *Frontiers in Cellular Neuroscience, 16*, 885190.
37. Zhu, L., Zhong, W., Meng, X., Yang, X., Zhang, W., Tian, Y., & Li, Y. (2024). Polymeric nanocarriers delivery systems in ischemic stroke. *Journal of Nanobiotechnology, 22*, 424.
38. Mozhdehbakhsh Mofrad, Y., Asiaei, S., Shaygani, H., & Salehi, S. S. (2024). Investigating magnetic hyperthermia parameters in glioblastoma treatment: An in silico study. *Results in Engineering, 23*, 102473.

39. Sheervalilou, R., Khoei, S., Khoee, S., Shirvaliloo, M., Sadri, E., Shirvalilou, S., & Goudarzi, M. (2023). Magnetohyperthermia-synergistic glioma therapy using magnetic graphene oxide nanoheaters. *Cancer Nanotechnology, 14*, 44.
40. Sahu SK, Gupta P, Keshri AK, Sahu DS, Verma VSV. Advances in Nanomedicine for Treatment of Neurological Disorders. *Journal of Pharmacology, Genetics and Molecular Biology*. Published online December 24, 2025:01-17. doi:10.64062/JPGMB.VOL1.ISSUE6.1
41. Beola, L., Iturrioz-Rodríguez, N., Pucci, C., Bertorelli, R., & Ciofani, G. (2023). Drug-loaded lipid magnetic nanoparticles for combined hyperthermia and chemotherapy. *ACS Nano, 17*, 18441–18455.
42. Soares Martins, T., Marçalo, R., da Cruz e Silva, C. B., Trindade, D., Catita, J., Amado, F., Melo, T., Rosa, I. M., Vogelgsang, J., & Wiltfang, J. (2022). Novel exosome biomarker candidates for Alzheimer's disease. *Molecular Neurobiology, 59*, 2838–2854.
43. Hu, S., Zhang, L., Su, Y., Liang, X., Yang, J., Luo, Q., & Luo, H. (2024). Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR. *Science Advances, 10*, eabm3088.
44. Kandimalla, R., Saeed, M., Tyagi, N., Gupta, R. C., & Aqil, F. (2023). Exosome-based approaches in the management of Alzheimer's disease. *Neuroscience & Biobehavioral Reviews, 144*, 104974.
45. Han, C., Zhang, A., Kong, Y., Yu, N., Xie, T., Dou, B., Li, K., Wang, Y., Li, J., & Xu, K. (2019). Iron oxide-carbon hybrid nanoparticles for dual-modal imaging. *Analytica Chimica Acta, 1067*, 115–128.
46. Danafar, H., Baghdadchi, Y., Barsbay, M., Ghaffarlou, M., Mousazadeh, N., & Mohammadi, A. (2023). Fe_3O_4–gold hybrid nanoparticles coated with albumin as MRI contrast agents. *Heliyon, 9*, e13874.
47. Chen, J., Guo, Z., Wang, H.-B., Gong, M., Kong, X.-K., Xia, P., & Chen, Q.-W. (2013). Fe_3O_4@C@Ag hybrid nanoparticles for dual imaging and NIR-responsive drug release. *Biomaterials, 34*, 571–581.
48. Terracciano, R., Demarchi, D., Ruo Roch, M., Aiassa, S., & Pagana, G. (2021). Nanomaterials to fight cancer: Their multifunctional exploitability. *Journal of Nanoscience and Nanotechnology, 21*, 2760–2777.
49. Walia, S., & Mehta, M. J. (2024). Recent progress on nanosystems for nucleic acid delivery. *RSC Pharmaceutics, 1*, 645–674.
50. Holghoomi, R., Kiani, M. H., Rahdar, A., Hashemi, S. M., Ferreira, L. F. R., & Fathi-Karkan, S. (2024). Nanoparticle-delivered gallic acid in cancer therapy. *Journal of Drug Delivery Science and Technology, 101*, 106129.
51. Shete, M. B., Patil, T. S., Deshpande, A. S., Saraogi, G., Vasdev, N., Deshpande, M., Rajpoot, K., & Tekade, R. K. (2022). Current trends in theranostic nanomedicines. *Journal of Drug Delivery Science and Technology, 71*, 103280.
52. Otero, M. M., Sneed, K. B., & Pathak, Y. V. (2024). Effects of nanotechnology and theranostics on neurodegenerative diseases. *Chemical and Pharmaceutical Research, 6*, 1–8.

53. García-Muñoz, R. A., McConnell, J., Morales, V., & Sanz, R. (2022). Designing nanocarriers for Parkinson's disease. *Neural Regeneration Research, 17*, 1743–1744.
54. Verma VS. Advanced Catalytic Materials and Processes in Hydrogen Technology. *SS Journal of Interconnected Education and Life Sciences (SSJIELS)*. 2025;01:16-26. https://ssjiels.nknpub.com/1/article/view/8
55. Verma VS. Development of Multi-Target Directed Ligands for Neurodegenerative Disorders: A Medicinal Chemistry Approach. *Interconnected Journal of Chemistry and Pharmaceutical Sciences (IJCPS)*. 2025;01:49-65. https://ijcps.nknpub.com/1/article/view/9
56. Abujamai, J., Satar, R., & Ansari, S. A. (2024). Designing and formulation of nanocarriers for Alzheimer's and Parkinson's early detection and therapy. *CNS & Neurological Disorders – Drug Targets, 23*, 1251–1262.
57. Lin, G., Pan, W., He, Y., Yi, X., Zhou, P., & Lu, J. (2024). Opportunities for 3D culture of MSC-derived exosomes. *Tissue Engineering Part B: Reviews, 30*, 462–476.
58. Sahu SK, Gupta P, Keshri AK, Sahu DS, Verma VSV. Advances in Nanomedicine for Treatment of Neurological Disorders. *Journal of Pharmacology, Genetics and Molecular Biology*. Published online December 24, 2025:01-17. doi:10.64062/JPGMB.VOL1.ISSUE6.1
59. Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023). Magnetic nanosystems for Alzheimer's disease theranostics. *Pharmaceutics, 15*, 2316.
60. Ashique, S., Afzal, O., Yasmin, S., Hussain, A., Altamimi, M. A., Webster, T. J., & Altamimi, A. S. A. (2023). Strategic nanocarriers to control neurodegenerative disorders. *International Journal of Pharmaceutics, 633*, 122614.
61. Verma VS, Sahu M. Synthesis And Characterization of NovelOrganometallic Complexes for CatalyticApplications. *Journal of Pharmaceutical Research and Integrated Medical Sciences*. 2025;2(4):60-70. https://www.aktpublication.com/index.php/jprims/article/view/61
62. Sahu SK, Gupta P, Keshri AK, Sahu DS, Verma VSV. Advances in Nanomedicine for Treatment of Neurological Disorders. *Journal of Pharmacology, Genetics and Molecular Biology*. Published online December 24, 2025:01-17. doi:10.64062/JPGMB.VOL1.ISSUE6.1
63. Wu, D.-D., Salah, Y. A., Ngowi, E. E., Zhang, Y.-X., Khattak, S., Khan, N. H., Wang, Y., Li, T., Guo, Z.-H., Wang, Y.-M., et al. (2023). Nanotechnology prospects in brain therapeutics via gene targeting and nose-to-brain delivery. *iScience, 26*, 107321.
64. Wu, C., Yang, L., Feng, S., Zhu, L., Yang, L., Liu, T. C.-Y., & Duan, R. (2022). Therapeutic non-invasive brain treatments in Alzheimer's disease: Advances and challenges. *Inflammation and Regeneration, 42*, 31.
65. Dewangan D, Nakhate KT, Verma VS, et al. Synthesis and Molecular Docking Study of Novel Hybrids of 1,3,4-Oxadiazoles and Quinoxaline as a Potential Analgesic and Anti-Inflammatory Agents. *J Heterocycl Chem*. 2018;55(12):2901-2910. doi:10.1002/JHET
66. Dohre PD, Verma VSV, Singh NS, Singh NS, Kumar DK. Phytopharmacology in the Nanotech Era: Bridging Natural Compounds with Pharmaceutical Nanocarriers. *Journal*

of Pharmacology, Genetics and Molecular Biology. Published online February 12, 2026:45-67. doi:10.64062/JPGMB.VOL2.ISSUE1.4

67. Dewangan G, Kumar N, Sahu VS, Kashyap G, Verma VSV. Realizing the Promise of Cancer Nanotechnology: From Therapeutic Platforms to Omics-Driven Precision Oncology and Clinical Translation. *Journal of Pharmaceutical Research and Integrated Medical Sciences*. Published online February 18, 2026:1-12. doi:10.64063/3049-1681.VOL.3.ISSUE2.1
68. Cano, A., Ettcheto, M., Bernuz, M., Puerta, R., Esteban de Antonio, E., Sánchez-López, E., Souto, E. B., Camins, A., Martí, M., & Pividori, M. I. (2023). Extracellular vesicles as mirrors of brain physiopathology. *International Journal of Biological Sciences, 19*, 721–743.
69. Bian, X., Yang, L., Jiang, D., Grippin, A. J., Ma, Y., Wu, S., Wu, L., Wang, X., Tang, Z., & Tang, K. (2024). Regulation of cerebral blood flow boosts brain targeting of vinpocetine-derived nanoparticles. *Nature Communications, 15*, 3987.
70. Sun, P. (2022). Use of nanoparticles to combat neurodegenerative disease. *NeurologyLive, 5*. https://www.neurologylive.com/view/use-of-nanoparticles-to-combat-neurodegenerative-disease
71. Dinger, N., Russo, C., Fusco, S., Netti, P. A., Sirignano, M., & Panzetta, V. (2024). Carbon quantum dots modulate breast cancer cell migration. *Nanotoxicology, 18*, 618–644.
72. Hemmati, A., Emadi, H., & Nabavi, S. R. (2023). Green synthesis of S/N-doped CQDs for L-DOPA detection. *ACS Omega, 8*, 20987–20999.
73. Kumar, J., Delgado, S. A., Sarma, H., & Narayan, M. (2023). Caffeic acid recarbonization: Green sustainable carbon nanomaterials to combat neurodegeneration. *Environmental Research, 237*, 116932.
74. Rai, G., Sharma, S., Singh, A., Chandekar, V., Rastogi, A., Gauba, P., Chaudhary, V., & Dang, S. (2024). Nanotechnological advancements for the treatment of neurodegenerative disorders. *Journal of Dispersion Science and Technology*, 1–19.
75. Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024). Multifunctional nanoparticle-mediated combination therapy for human diseases. *Signal Transduction and Targeted Therapy, 9*, 1.